Physician profile
Kapil Arya
NPI 1538319884
$16,129.32
in general payments reported to CMS, 2019-2025
9 companies · $4,124 in 2025
The $4,124 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.17 · 2020: $755 · 2021: $75.00 · 2022: $47.31 · 2023: $7,786 · 2024: $3,307 · 2025: $4,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,585 · Honoraria: $2,826 · Food and Beverage: $2,079 · Travel and Lodging: $1,587 · Gift: $100 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,585.00 |
| Honoraria | $2,825.50 |
| Food and Beverage | $2,078.96 |
| Travel and Lodging | $1,587.38 |
| Gift | $100.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $9,017.65 | 2023-2025 | Evrysdi |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $3,729.37 | 2020-2023 | Zolgensma |
| Genentech, INC. | $2,971.35 | 2022-2024 | Evrysdi |
| Neuropace, INC. | $150.78 | 2023 | |
| J2 Bio-Pharma LLC | $100.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $62.53 | 2025 | |
| Biomarin Pharmaceutical INC. | $38.00 | 2020 | |
| Biogen, INC. | $35.17 | 2019 | |
| Sarepta Therapeutics, INC. | $24.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kapil Arya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.